Posted on June 4th, 2013 by
Among women with Stage IV, estrogen receptor-positive breast cancer, the Oncotype DX® breast cancer test provided information about cancer prognosis; this may help guide treatment decisions. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The Oncotype DX breast cancer test evaluates the activity of certain genes in a sample of tumor tissue. The test provides information about the likelihood of chemotherapy benefit and the risk of cancer recurrence for women with early-stage, hormone receptor-positive, invasive breast cancer. The Recurrence Score that is generated by the test ranges from 0 to 100, with higher scores indicating a higher risk of recurrence. A version of the test is also available for women with ductal carcinoma in situ (DCIS) of the breast.
To assess the Oncotype DX test among women with advanced breast cancer, researchers evaluated 102 women with Stage IV breast cancer.
These results suggest that the Oncotype DX breast cancer test provides information about the prognosis of Stage IV, estrogen receptor-positive breast cancer. Additional research would help to determine whether women who have a particularly poor prognosis based on the test benefit from more aggressive treatment.
Reference: King TA, Lyman JP, Gonen M et al. prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer. Presented at the 49th Annual Meeting of the American Society of Clinical Oncology. May 31-June 4, 2013; Chicago, IL. Abstract 507.
Copyright © 2013 CancerConsultants. All Rights Reserved.
You must be logged-in to the site to post a comment.
Page loaded in 0.487 seconds